CoChat

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease

Burns, A., Spiegel, R., Quarg, P. · 2004 · International Journal of Geriatric Psychiatry
Cited by 65

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Cholinesterase (ChE) inhibitors are primarily used in the treatment of mild to moderate Alzheimer's disease (AD), but may also be effective in more severe disease. Objective: To evaluate the dual ChE inhibitor, rivastigmine, in more severe dementia. Methods: We retrospectively analysed pooled data from three randomised, placebo‐controlled, double‐blind, 6‐month trials, involving 2126 AD subjects. Subjects were selected according to baseline Mini‐Mental State Examination (MMSE) score to identify subjects with more severe cognitive impairment (10–12 MMSE points). One‐hundred‐and‐seventeen subjects were included who had been treated with rivastigmine 6–12 mg/day or placebo. The AD Assessment Scale‐Cognitive Subscale (ADAS‐Cog), the MMSE, a six‐item subscore of the Progressive Deterioration Scale (PDS) and the BEHAVE‐AD assessed efficacy. Tolerability was assessed by recording adverse events (AEs) and the relative risk (RR) of discontinuation. Results: This group of subjects responded well to rivastigmine. After 6 months, the mean ADAS‐Cog score declined by 6.3 points in the placebo group and increased by 0.2 points in the rivastigmine group (observed cases; p<0.001). Clinical benefits were also observed with the MMSE, the six‐item PDS score and items of the BEHAVE‐AD. Rivastigmine showed the same pattern of AEs as in other studies, but the RR of dropping out due to AEs was lower than in subjects with milder AD. Conclusion: Current treatment guidelines do not recommend treating individuals with severe AD with ChE inhibitors. However, this retrospective analysis suggests that rivastigmine 6–12 mg/day may benefit subjects with more severe disease, as well as subjects with mild to moderate impairment. Copyright © 2004 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gps.1058

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 65

Metadata

Authors
Burns, A., Spiegel, R., & Quarg, P.
Venue
International Journal of Geriatric Psychiatry
Publisher
Wiley
Published
2004-02-16
Volume
19
Issue
3
Pages
243-249
ISSN
  • 0885-6230 (ISSN-L)
  • 1099-1166
OpenAlex
W2037468903
Cited by
65
References
5
FWCI
4.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.